Xu, Yan

Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells

Hao, M., Zhang, L., An, G., Sui, W., Yu, Z., Zou, D., Xu, Y., Chang, H., & Qiu, L. (2011) · Journal of Hematology & Oncology

Multiple Myeloma Research and TreatmentsMicroRNA in disease regulation

Cited by 77

Low serum mi R‐19a expression as a novel poor prognostic indicator in multiple myeloma

Hao, M., Zang, M., Wendlandt, E., Xu, Y., An, G., Gong, D., Li, F., Qi, F., Zhang, Y., Yang, Y., et al. (2015) · International Journal of Cancer

Multiple Myeloma Research and TreatmentsMicroRNA in disease regulation

Cited by 72

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Yu, T., Chaganty, B., Lin, L., Xing, L., Ramakrishnan, B., Wen, K., Hsieh, P. A., Wollacott, A., Viswanathan, K., Adari, H., et al. (2020) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 43

Downregulated miR-33b is a novel predictor associated with disease progression and poor prognosis in multiple myeloma

Li, F., Hao, M., Feng, X., Zang, M., Qin, Y., Yi, S., Li, Z., Xu, Y., Zhou, L., Sui, W., et al. (2015) · Leukemia Research

Multiple Myeloma Research and TreatmentsMicroRNA in disease regulation

Cited by 25